Clinical and biochemical characteristics of patients with acromegaly and normal or increased prolactin levels DOI Creative Commons

Yu. A. Ukhanova,

Irena Ilovayskaya

Almanac of Clinical Medicine, Journal Year: 2024, Volume and Issue: 52(6), P. 331 - 341

Published: Dec. 16, 2024

Background: Prevalence of hyperprolactinemia in patients with acromegaly is 30 to 40%. Since recently, the necessity screening for hyperprolactinemic pituitary adenoma has been actively debated. The literature on this issue controversial, some authors describing significant differences clinical and biochemical parameters normal or increased prolactin levels, while others state absence such differences. Aim: To identify hallmarks level. Methods: We performed a single center, sample retrospective, observational cohort uncontrolled non-interventional study 306 (70 men 236 women) examined from July 2021 June 2024, 50 them microadenomas 256 macroadenomas. were divided into two groups: without (n = 234) 72). groups compared age, gender, manifestations, insulin-like growth factor 1 (IGF1) characteristics adenomas efficacy treatment. In we additionally analyzed levels at disease manifestation, an association between suprasellar prolactin, volume onset, before Results: Hyperprolactinemia was significantly less common, than hyperprolactinemia, associated acromegalic enlargement face (odds ratio [OR] 0.34, 95% confidence interval [CI] 0.19–0.62, р 0.001), hands feet (OR 0.06, CI 0.03–0.12, but more common visual field derangement 2.8, 1.06–7.39, 0.043), menstrual cycle abnormalities women 4.11, 2.14–7.88, 0.001) breast discharge 18.71, 4–87.61, 0.001). noticed their first symptoms younger age (median 37 [25; 46] years vs 41.5 [32; 51.5] years, 0.004) diagnosed also earlier, (45 [34.5; 55] 52 [42; 61] There no latency, activity gender distribution. larger, that (4445 [1649; 7767] mm3 1242 [448; 3740] mm3, No correlation found levels. rates control both not different. Conclusion: results our emphasize importance exclude prolactinomas those suspected stalk compression (which characterized by moderate adenoma), even pathognomic signs secretion hormone. does affect treatment outcomes acromegaly, frequent administration dopamine receptor agonists result proportion main disease.

Language: Английский

Pharmacoeconomic analysis of lanreotide and prolonged-release octreotide in first- and second-line therapy of acromegaly DOI Creative Commons
I. Krysanov, Е. В. Макарова,

V. Yu. Ermakova

et al.

FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology, Journal Year: 2025, Volume and Issue: 18(1), P. 22 - 31

Published: May 2, 2025

Background . Pharmacoeconomic aspects of somatostatin analogues remain an important topic for discussion. Despite the higher cost lanreotide compared to octreotide, former may have advantage in terms administration convenience and high efficacy. Objective : carry out a cost-effectiveness analysis (CEA) use prolonged-release octreotide adult patients with acromegaly. Material methods A model treatment acromegaly during period 2.5 years was developed, accounting direct medical costs drugs surgical intervention. pharmacoeconomic study by CEA method sensitivity were performed. Results In real clinical practice treatment, enables more effective remission (51% vs 24%) under comparable safety profile. The 2.5-year course amounted 1,466,669.49 rubles per patient 908,272.53 octreotide. Considering difference amount 558,096.79 rubles, found be 25% expensive. According results, achieving 1 equal 2,415,036.25 3,676,115.43 respectively. Therefore, over years, saving 1,261,079.17 (52%). demonstrated robustness initial against increase price up 64%, frequency surgery receiving 302%, decrease remissions 35%. Conclusion is clinically cost-effective approach context Russian healthcare system.

Language: Английский

Citations

0
Obesity in a patient with acromegaly: a case report DOI Creative Commons

Georgy Gabaidze,

M. A. Perepelova, Elena Przhiyalkovskaya

et al.

Obesity and metabolism, Journal Year: 2024, Volume and Issue: 21(3), P. 331 - 338

Published: Sept. 27, 2024

Acromegaly is a severe neuroendocrine disease characterized by excessive production of the growth hormone (GH). The slow development symptoms increases diagnostic search up to 15 years. Permanent effect on human body can cause structural and functional disorders organs. main complications acromegaly include cardiovascular, respiratory, musculoskeletal system dysfunction, as well impaired carbohydrate metabolism an increased risk developing neoplasms. Often, nonspecific be masked other pathologies or their complications, such obesity. An increase in subcutaneous fat, blood pressure, joint pain, edema, lipid are observed both additional factor obesity complication sleep apnea, which triggers series pathological processes that ultimately lead Pickwickian syndrome. We present clinical case patient with obesity, discussing effects excess weight course underlying disease, presence individual approach treatment.

Language: Английский

Citations

0
Clinical and biochemical characteristics of patients with acromegaly and normal or increased prolactin levels DOI Creative Commons

Yu. A. Ukhanova,

Irena Ilovayskaya

Almanac of Clinical Medicine, Journal Year: 2024, Volume and Issue: 52(6), P. 331 - 341

Published: Dec. 16, 2024

Background: Prevalence of hyperprolactinemia in patients with acromegaly is 30 to 40%. Since recently, the necessity screening for hyperprolactinemic pituitary adenoma has been actively debated. The literature on this issue controversial, some authors describing significant differences clinical and biochemical parameters normal or increased prolactin levels, while others state absence such differences. Aim: To identify hallmarks level. Methods: We performed a single center, sample retrospective, observational cohort uncontrolled non-interventional study 306 (70 men 236 women) examined from July 2021 June 2024, 50 them microadenomas 256 macroadenomas. were divided into two groups: without (n = 234) 72). groups compared age, gender, manifestations, insulin-like growth factor 1 (IGF1) characteristics adenomas efficacy treatment. In we additionally analyzed levels at disease manifestation, an association between suprasellar prolactin, volume onset, before Results: Hyperprolactinemia was significantly less common, than hyperprolactinemia, associated acromegalic enlargement face (odds ratio [OR] 0.34, 95% confidence interval [CI] 0.19–0.62, р 0.001), hands feet (OR 0.06, CI 0.03–0.12, but more common visual field derangement 2.8, 1.06–7.39, 0.043), menstrual cycle abnormalities women 4.11, 2.14–7.88, 0.001) breast discharge 18.71, 4–87.61, 0.001). noticed their first symptoms younger age (median 37 [25; 46] years vs 41.5 [32; 51.5] years, 0.004) diagnosed also earlier, (45 [34.5; 55] 52 [42; 61] There no latency, activity gender distribution. larger, that (4445 [1649; 7767] mm3 1242 [448; 3740] mm3, No correlation found levels. rates control both not different. Conclusion: results our emphasize importance exclude prolactinomas those suspected stalk compression (which characterized by moderate adenoma), even pathognomic signs secretion hormone. does affect treatment outcomes acromegaly, frequent administration dopamine receptor agonists result proportion main disease.

Language: Английский

Citations

0